Latest news with #regenerativemedicine
Yahoo
5 days ago
- Health
- Yahoo
Scientists Found the Staggering Natural Switch That Could Bring Back Your Eyesight
What if your eyes could fix themselves? Turns out, your body might already have what it takes to regrow the cells you need to see better—and scientists may have found the switch to simply turn it back on. Researchers in South Korea found a protein, PROX1, that acts sort of like a molecular gatekeeper, suppressing your body's natural ability to regrow damaged retinal cells. When the scientists blocked PROX1 in mice, something incredible happened: they regenerated essential vision cells for a whopping six months. For mice, that's a huge milestone. Zebrafish and amphibians have done this naturally for ages, but the regenerative implications for mammals—and maybe humans—are seismic. Watch Pop Mech editors Andrew Daniels and Manasee Wagh discuss the new discovery that could reshape how we treat blindness. Andrew and Manasee break down why this is such a groundbreaking moment in regenerative medicine, how retinal cells are basically extensions of your brain, and what this new study could mean for millions of people (and Andrew's dog) suffering from degenerative eye diseases. Along the way, they also explore other mind-blowing methods for restoring eyesight, including one that uses gold nanoparticles and lasers—yes, really. Watch the full episode above now, and find more installments of the Astounding Pop Mech Show on You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life? Solve the daily Crossword
Yahoo
5 days ago
- Business
- Yahoo
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan
In connection with HekaBio's recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan. Under Japan's Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class forerunner for the treatment of several intractable neurodegenerative diseases. SANTA ANA, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, and HekaBio K.K., headquartered in Chuo-ku, Tokyo ('HekaBio'), announced a strategic partnership to accelerate the regulatory, manufacturing and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan following HekaBio's recently announced investment in common equity of NKGen. HekaBio will lead all clinical trials in Japan and oversee all regulatory activities with Japan's Pharmaceuticals and Medical Devices Agency for pre-market approval of troculeucel in several neurodegenerative disease indications, including Alzheimer's and Parkinson's Diseases. As troculeucel is an autologous, non-genetically modified cell therapy, there is allowance under regenerative medicine regulations in Japan to offer this therapy to patients on an accelerated path, much faster than in other major markets. HekaBio will fully leverage the regulation and its domestic strategic partner network, aiming for first dosing in Japanese patients over the next 12 months. Beyond intractable disease, troculeucel has the potential to also support Japan's aging population in the longevity/wellness space. 'Japan has always had an advanced progressive health care system where great attention has been placed on the use of novel autologous cell therapies for prevention, longevity, and wellness as well as for the treatment of more chronic illnesses,' said Paul Y. Song, MD, Chairman and Chief Executive Officer ('CEO') of NKGen. 'I am convinced that HekaBio's clinical, regulatory, and commercial expertise will guide us to satisfy all regulatory requirements, find the best local manufacturing partner to make our therapy readily available, and ultimately develop the best commercial strategy for Japan. We are very excited to partner with HekaBio.' 'Dementia, particularly Alzheimer's Disease, and other neurodegenerative diseases together present significant health and social challenges in Japan due to the country's aging population. We are very excited about our partnership with NKGen and look forward to advancing troculeucel for the benefit of patients and society,' said Rob Claar, CEO of HekaBio. About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About HekaBio HekaBio is a Japan-based healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage yet de-risked opportunities in CNS, oncology and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, please visit Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact: Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contact: Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@
National Post
14-07-2025
- Health
- National Post
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
Article content Preclinical data highlight the potential of Aspect's adrenal Bioprinted Tissue Therapeutics to restore adrenal function and treat primary adrenal insufficiency Article content VANCOUVER, British Columbia — Aspect Biosystems, a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) as a new category in regenerative medicine, today announced new preclinical data at ENDO 2025, the Endocrine Society's annual meeting held in San Francisco. The company presented an oral and poster presentation highlighting that Aspect's adrenal BTTs can restore adrenal function, following natural daily hormone rhythms and maintaining long-term performance in animal models of primary adrenal insufficiency. Article content Primary adrenal insufficiency is a serious, life-threatening condition in which the adrenal glands fail to produce sufficient levels of essential hormones such as cortisol, a key regulator of the body's stress response. The current standard of care involves daily hormone replacement therapy, which does not fully replicate the body's natural circadian hormone rhythms and is associated with significant drug-related side effects. This can leave patients with a poor quality of life and at risk of ongoing health challenges, including potentially fatal adrenal crises. Aspect's adrenal BTTs were developed using the company's proprietary full-stack tissue therapeutic platform, which combines AI-powered bioprinting, computational design tools, therapeutic cells, and advanced biomaterials. Article content In preclinical studies, adrenal BTTs containing human adrenal cells were implanted into adrenalectomized mice. These BTTs produced cortisol in response to adrenocorticotropic hormone (ACTH) stimulation—which is normally secreted from the brain—and followed the animals' natural circadian fluctuations in hormone levels. When exposed to high levels of injected ACTH, these mice demonstrated rapid increases in circulating cortisol, confirming that the adrenal BTTs were functionally responsive. In contrast, control animals receiving cell-free implants showed no significant cortisol levels and did not respond to ACTH stimulation. Importantly, adrenal BTTs remained functional in vivo throughout the study period of over six months and improved animal survival. Article content 'Our research shows that Aspect's adrenal BTTs successfully replicate healthy human adrenal gland function by releasing cortisol in a pattern that follows the natural daily rhythms of hormone release and by responding appropriately to a stimulus that mimics a stress response,' said Sam Wadsworth, PhD, Chief Scientific Officer at Aspect Biosystems. 'These results demonstrate that our off-the-shelf, implantable cell therapy can work in harmony with the body's physiology and has real potential to serve as a functional cure for primary adrenal insufficiency.' Article content 'At Aspect, we're making breakthrough progress with our Bioprinted Tissue Therapeutics platform to restore complex biological functions across a range of serious endocrine and metabolic diseases,' said Tamer Mohamed, Chief Executive Officer of Aspect Biosystems. 'This latest advance in primary adrenal insufficiency, a rare and life-threatening condition with limited treatment options, showcases the potential of a bioengineered cell therapy to recreate natural hormone function and deliver a truly disease-modifying solution. This reflects our mission to develop regenerative medicines capable of achieving functional cures for patients with serious and underserved diseases.' Article content About ENDO Article content Hosted by the Endocrine Society, ENDO is the leading global meeting on endocrinology research and clinical care. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions. Learn more at Article content About Aspect Biosystems Article content Aspect Biosystems is a biotechnology company pioneering the development of Bioprinted Tissue Therapeutics (BTTs) to transform how we treat some of the most elusive diseases. Aspect's BTTs are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of BTTs across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity. For more information, please visit and follow on LinkedIn. Article content Article content Article content Article content
Yahoo
14-07-2025
- Business
- Yahoo
Adia Nutrition Inc. Celebrates Grand Opening of Adia Med of San Antonio, First Licensed Clinic, Led by Michele DeLeon MD
Winter Park, Florida--(Newsfile Corp. - July 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), an emerging leader in regenerative medicine, proudly announces the grand opening of Adia Med of San Antonio, its first licensed clinic under a strategic license agreement, located at 18707 Hardy Oak Blvd, Suite 500, San Antonio, Texas 78258. Headed by esteemed wellness regenerative expert Michele DeLeon MD, this cutting-edge facility marks a significant step in expanding access to innovative regenerative therapies across the United States. Adia Med of San Antonio will offer FDA-registered products, including AdiaVita The Most Trusted Brand (umbilical cord stem cells with 100 million viable cells and 3 trillion exosomes per unit) and AdiaLink (3.5 trillion exosomes per unit). Additionally, Adia Med of San Antonio will collaborate with Adia Med of Winter Park in a groundbreaking clinical study exploring regenerative therapies for autism, further advancing the company's commitment to transformative healthcare solutions. "We are thrilled to launch Adia Med of San Antonio as our first licensed clinic, under the exceptional leadership of Michele DeLeon MD," said Larry Powalisz, CEO of Adia Nutrition Inc. "This vibrant new location, combined with clinical study for autism alongside Adia Med of Winter Park, is a testament to our unwavering commitment to transforming lives through cutting-edge care. San Antonio is just the beginning of an exciting new chapter for Adia Nutrition." "Equipped with state-of-the-art technology and staffed by a highly trained team, Adia Med of San Antonio upholds the rigorous standards of Adia Nutrition's existing clinics, including Adia Med Winter Park. For those interested in licensing Adia Med's name and becoming part of its innovative network, please reach out to ceo@ or call 321-788-0850 for more information. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Associated Press
13-07-2025
- Health
- Associated Press
Lydian Announces Non-Invasive Orthopedic Stem Cell Treatments In Guro, Seoul
Lydian Cosmetic Surgery Clinic announces its autologous stem cell treatments in Guro district, offering non-surgical internal medicine therapies for joint pain and other chronic conditions under Dr. Abraham An's supervision at their Ministry-approved Gangnam facility. Seoul, Korea, Republic of, July 13, 2025 -- The Lydian Cosmetic Surgery Clinic in Gangnam, Seoul, has announced its autologous stem cell treatments for orthopedic applications—all supervised by Dr. Abraham An, the clinic's head physician. For more information, visit These treatments address chronic conditions such as joint pain and age-related degeneration of the joints, tendons, ligaments, and other tissues. Lydian has conducted stem cell research since 2005 and holds Ministry of Health and Welfare approval as an advanced regenerative medicine institution. This official recognition places the clinic among select facilities authorized to perform advanced regenerative procedures in South Korea. The clinic's autologous approach uses cells from the patient's own body, reducing rejection possibilities. Lydian extracts stem cells through three methods—from blood, bone marrow, and fat tissues—allowing for personalized treatment protocols based on specific patient requirements. This multi-source extraction capability represents a significant advancement over single-source methods. Safety remains paramount at the facility, which maintains a Class sterile room with 10,000-level cleanliness standards to prevent contamination during cell processing. This controlled environment preserves cell quality before reinjection. The clinic's commitment to sterile processing helps ensure the integrity of the extracted stem cells throughout the treatment process. The non-surgical injection method differs from surgical stem cell treatments that require incisions and carry higher complication risks. Lydian's process involves extracting cells, processing them under controlled conditions, and administering them through targeted injections. This approach typically results in shorter recovery times compared to surgical alternatives, a critical factor for those with limited mobility due to orthopedic problems. The clinic's research background spans nearly two decades, during which they have refined their stem cell extraction and processing techniques. This long-term research focus has enabled the development of specialized protocols for various internal medicine applications, particularly for chronic conditions that may benefit from regenerative approaches. Located at 836 Nonhyeon-ro in Sinsa-dong, Gangnam, the clinic welcomes patients from the Guro district interested in these specialized treatments. To learn more about Lydian Cosmetic Surgery Clinic's orthopedic stem cell treatments, visit Contact Info: Name: Dr. Abraham An Email: Send Email Organization: Lydian Cosmetic Surgery Clinic Address: 836 Nonhyeon-ro, Sinsa-dong, Gangnam, Seoul, Seoul 06025, Korea, Republic of Phone: +82-10-9692-5508 Website: Release ID: 89164570 In the event of detecting errors, concerns, or irregularities in the content shared in this press release that require attention or if there is a need for a press release takedown, we kindly request that you inform us promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your feedback within 8 hours and take necessary actions to resolve any identified issues diligently or guide you through the removal process. Providing accurate and dependable information is our utmost priority.
